Factor XIII @entity22653 polymorphism, factor XIII antigen levels and activity and the risk of XXXX .

@entity1 @entity22653 @entity49 @entity1150 @entity2596 @entity715
Varying results on the effect of factor XIII (FXIII) @entity22653 on venous @entity715 risk have been reported. The probability of a true association between this polymorphism and venous @entity715 risk would be enhanced by a laboratory phenotype associated with this polymorphism and with the @entity715 risk. The aim of this study was to assess the effect of FXIII @entity22653 , FXIII activity and subunit levels on venous @entity715 risk in a large case-control study, The Leiden @entity49 study (LETS). We found higher FXIII activity for 34Leu carriers (Leu/Leu: 158.0, @entity2596 / @entity2596 : 95.0). FXIII subunit levels were not associated with genotype. Higher FXIII activity was associated with a slightly decreased @entity715 risk [Odds ratio (OR): 0.8, 95% confidence intervals (CI): 0.5-1.3]. This effect was not present for elevated FXIII subunit levels. Higher FXIII activity was also associated with a higher dissociation index (percentage A2B2 complex dissociated after activation by thrombin for a fixed time interval). This index was higher for FXIII 34Leu carriers. The risk of @entity1150 was slightly decreased for carriers of the 34Leu allele [OR: 0.9 (95%CI: 0.7-1.1)]. For homozygous 34Leu carriers the OR was 0.7 (95%CI: 0.4-1.3). This finding, suggesting a weak protective effect, was completely restricted to @entity1 . An overall estimate of @entity715 risk was calculated by using earlier reports on the risk of FXIII @entity22653 . The overall risk estimate for homozygous 34Leu carriers was 0.8 (95%CI: 0.6-1.0). In this study, a weak protective effect against @entity49 was found, of FXIII 34Leu as well as of increased FXIII activity.
